RS4

DJI RS 4 and RS 4 Pro Gimbals and the Focus Pro DJI Announced; YouTube Video First Look. Now In Stock at B&H

Retrieved on: 
Tuesday, April 9, 2024
RS4, FPV, DJI, B&H, Focus, Wind, Carbon, POV, FIZ, Lens, AMF, Torque, OLED, Lidar, Rōnin, Telescopic sight

NEW YORK, April 9, 2024 /PRNewswire/ -- B&H is pleased to announce innovative new stabilizer systems from industry-leader DJI: the RS 4 and RS 4 Pro gimbals. The new DJI stabilizers are joined by a stand-alone Focus Pro system with LiDAR autofocus technology.

Key Points: 
  • DJI continues to offer innovative gimbal systems with the introduction of the new RS 4 , the robust RS 4 Pro , and the independent Focus Pro lens control system.
  • NEW YORK, April 9, 2024 /PRNewswire/ -- B&H is pleased to announce innovative new stabilizer systems from industry-leader DJI: the RS 4 and RS 4 Pro gimbals.
  • The new DJI stabilizers are joined by a stand-alone Focus Pro system with LiDAR autofocus technology.
  • Thanks to Teflon coatings on all three axes, balancing on the new RS4 gimbals is smoother than ever before.

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

Retrieved on: 
Friday, June 9, 2023
Lymphoma, MDM2, St. Michael's Indian Residential School (Alert Bay), Arm, IV, European Hematology Association, ALL, Acute lymphoblastic leukemia, Neoplasm, Therapeutic index, SMI, TPD, RS4, Acute myeloid leukemia, Congress, AML, Patient, Apoptosis, Cancer, EHA, Acute leukemia, Leukemia, Therapy, Safety, Vaccine, Pharmaceutical industry

The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.

Key Points: 
  • The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.
  • KT-253 targets MDM2, the crucial regulator of the most common tumor suppressor, p53.
  • p53 remains intact (wild type) in close to 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • Patients in the KT-253 Phase 1 dose escalation study will receive IV doses of KT-253 administered once every 3 weeks.

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Neoplasm, PDX, Entrepreneurship, Annual report, Lymphatic system, Therapy, Security (finance), Lymphoma, Smis, Safety, Science, Biotechnology, CDX, ASH, STAT3, RS4, AML, Boston, Venetoclax, Boston Business Journal, Risk, Society, IND, Apoptosis, COVID-19, Patient, MDM2, Vaccine, Pharmaceutical industry, IRAK4, DLBCL, Black Majesty

WATERTOWN, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today presented preclinical data showing that KT-253, a novel MDM2 degrader, inhibited tumor growth as single agent and in combination with venetoclax in AML xenograft models. The data was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The data was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.
  • The murine double minute 2 (MDM2) oncoprotein is the E3 ligase that ubiquitinates and degrades the p53 tumor suppressor.
  • Recent clinical trials with MDM2 inhibitors, especially in relapsed/refractory Acute Myeloid Leukemia (AML), have resulted in suboptimal clinical activity, highlighting the need for novel therapeutic approaches to treat WT p53 hematologic and solid tumor malignancies.
  • Kymera previously showed that KT-253, a novel, highly potent and selective heterobifunctional MDM2 degrader, has superior activity compared to MDM2 SMIs and demonstrated greater than 200-fold improvements in both in vitro cell growth inhibition and apoptosis.

First Annual Insider Risk Excellence Award Winners Protect Sensitive Company Data and Intellectual Property in Groundbreaking Ways

Retrieved on: 
Thursday, March 24, 2022
Technology, Internet, Data Management, Security, Risk, RS4, Elevate, Organization, Snowflake, Risk management, Theft, Transport, Growth, CrowdStrike, Research, FinancialForce.com, GE Renewable Energy, Technology, Lyft, Twitter, Time, Salesforce, Solution, News, IRM, Year, Splunk, HR, IP, Medical imaging

Today, the Insider Risk Summit team announced the winners for the first annual Insider Risk Excellence Awards.

Key Points: 
  • Today, the Insider Risk Summit team announced the winners for the first annual Insider Risk Excellence Awards.
  • The cybersecurity awards recognize organizations and individuals who have implemented Insider Risk Management (IRM) programs in innovative ways to protect sensitive company data and intellectual property from loss, leak and theft while supporting the collaborative work of remote workforces.
  • Insider Risk Practitioner of the Year for individuals who have cultivated a powerful Insider Risk Management program for his or her organization.
  • The awards judges included:
    Wendy Overton, director of cyber strategy and insider risk leader, Optiv
    The third annual Insider Risk Summit will be held virtually on Sept. 20-22, 2022.

Accell Debuts Its Next-Generation Thunderbolt 4 Docking Station

Retrieved on: 
Wednesday, November 17, 2021
Thunderbolt, USB, CEC, Heart, Sigma 35 mm f/1.4 DG HSM lens, SSD, PD, HDMI, Technology, Data-rate units, 11, Seamless, MacOS, Solution, Microsoft, Sales & Marketing Executives International, MSRP, Support, Atmosphere of Earth, MacBook Pro, SD, Windows 10, Silicon, Marketing, UHS-II, Accell, MacBook Air, DisplayPort, RS4, Warehouse, Video game console

The Thunderbolt 4 Docking Station allows multiple peripheral connections to your systems through one single Thunderbolt 4 cable, becoming a power hub for the technology that surrounds you.

Key Points: 
  • The Thunderbolt 4 Docking Station allows multiple peripheral connections to your systems through one single Thunderbolt 4 cable, becoming a power hub for the technology that surrounds you.
  • With 40 Gbps bandwidth, the Thunderbolt 4 certified docking station supports high speed data transfer, 8K video, power delivery and more.
  • Compatibility is key, which is why the Thunderbolt 4 Docking Station works with Microsoft Windows 10 (RS4 and above) and Microsoft Windows 11 Thunderbolt 4 enabled laptops (Intel Evo Platforms) and macOS 11 (Big Sur and newer) MacBook Pro and MacBook Air with Thunderbolt 3 or Thunderbolt 4 ports.
  • The benefits and key features of Thunderbolt 4 Docking include:
    Expanded ports: Thunderbolt 4 Docking Station equips users to increase the number of devices by connecting to a laptop or desktop PC.